摘要
目的 探讨10批不同来源米槁挥发油对心肌损伤大鼠的治疗作用,并结合熵权法对比分析不同来源米槁挥发油对心肌损伤大鼠的治疗活性。方法 建立心肌损伤大鼠模型,采用Western blotting检测心肌组织中Bax/Bcl-2蛋白,实时荧光定量PCR技术(Real-time Quantitative PCR,RT-qPCR)检测心肌组织中成纤维细胞生长因子2(fibroblast growth factor-2,FGF-2)水平,免疫组织化学法(immunochemistry,IHC)分析10批不同来源的米槁挥发油治疗心肌损伤大鼠的心肌及主动脉组织的纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)及组织型纤溶酶原激活物(tissue plasminogen activator,TPA)的表达,苏木素-伊红染色法(Hematoxylin-eosin staining,HE)检测心肌组织的病变情况,通过熵权法综合评价10批不同来源米槁挥发油对心肌损伤大鼠的治疗效果。结果 10批不同来源的米槁挥发油均可使心肌组织中Bax/Bcl-2水平降低,FGF-2水平升高,心肌和主动脉组织的PAI-1水平降低,并升高TPA水平,缓解心肌组织的病变。熵权法计算结果以心肌组织中TPA的权重最大,贵州罗甸双江镇(2019年10月)、册亨县林木村(2019年10月)米槁挥发油综合评分最高,贵州罗甸罗悃镇(2018年9月)、罗甸罗悃镇(2018年10月)米槁挥发油评分最低。结论 10批不同来源米槁挥发油均可能通过调节Bax/Bcl-2蛋白的表达,升高FGF-2水平,增加纤溶系统阻止纤溶蛋白在血管沉积和血栓形成的能力,从而实现对心肌损伤大鼠的治疗作用。其中不同来源米槁挥发油的治疗能力存在一定差异,以贵州罗甸双江镇(2019年10月)、册亨林木村(2019年10月)米槁挥发油治疗效果相对较优,贵州罗甸罗悃镇(2018年9月)、罗甸罗悃镇(2018年10月)米槁挥发油治疗效果相对较差,可为后续米槁挥发油治疗心肌损伤的研究提供参考。
OBJECTIVE To explore the therapeutic effect of 10 batches of volatile oil from different sources of Cinnamomum migao H.W.Li on rats with myocardial injury,and to analyze the therapeutic activity of volatile oil from different sources of Cinnamomum migao H.W.Li on rats with myocardial injury in combination with entropy weight method.METHODS A rat model of myocardial injury was established.Western blotting was used to detect the levels of Bax/Bcl-2 proteins in myocardial tissue.Real-time quantitative PCR(RT-qPCR)was employed to measure the levels of fibroblast growth factor 2(FGF-2)in myocardial tissue.Immunohistochemistry(IHC)was used to analyze the expression of plasminogen activator inhibitor 1(PAI-1)and tissue plasminogen activator(TPA)in myocardial and aortic tissues of rats with myocardial injury treated with volatile oils from 10 batches of different sources of Cinnamomum migao H.W.Li.Hematoxylin-eosin(HE)staining was performed to assess the pathological changes in myocardial tissue.The entropy weight method was used to comprehensively evaluate the therapeutic effects作者简介:朱小婷,女,硕士生E-mail:1585958947@qq.com*通信作者:刘杰,女,博士,副教授E-mail:xiaojie0716@126.com Chin J Mod Appl Pharm,2024 September,Vol.41,No.17中国现代应用药学2024年9月第41卷第17期·2318·Chin J Mod Appl Pharm,2024 September,Vol.41,No.17 of the 10 batches of volatile oils from different sources on myocardial injury in rats.RESULTS The volatile oils from 10 batches of Cinnamomum migao H.W.Li from different sources could reduce the Bax/Bcl-2 levels in myocardial tissue,increase the FGF-2 levels,reduce the PAI-1 levels in myocardial and aortic tissues,and increase the TPA levels,and alleviating lesions in myocardial tissue.The results of the entropy weight method showed that the weight of TPA in myocardial tissue was the highest,the comprehensive scores for the volatile oils from Cinnamomum migao H.W.Li from Shuangjiang Town,Luodian County,Guizhou Province(October 2019)and Linmu Village,Ceheng County,Guizhou Province(October 2019)were the highest,while the scores for the volatile oils from Luokun Town,Luodian County,Guizhou Province(September 2018)and Luokun Town,Luodian County,Guizhou Province(October 2018)were the lowest.CONCLUSION The volatile oils from 10 batches of Cinnamomum migao H.W.Li from different sources may exert therapeutic effects on myocardial injury in rats by regulating the expression of Bax/Bcl-2 proteins,increasing FGF-2 levels,and enhancing the fibrinolytic system’s ability to prevent the deposition of fibrin in blood vessels and thrombus formation.There are certain differences in the therapeutic capabilities of the volatile oils from different sources,with the oils from Shuangjiang Town,Luodian County,Guizhou Province(October 2019)and Linmu Village,Ceheng County,Guizhou Province(October 2019)showing relatively better therapeutic effects,while those from Luokun Town,Luodian County,Guizhou Province(September 2018)and Luokun Town,Luodian County,Guizhou Province(October 2018)showing relatively poorer effects,this can provide a reference for the subsequent development of Cinnamomum migao H.W.Li volatile oils for the treatment of myocardial injury.
作者
朱小婷
徐剑
郭江涛
张永萍
刘杰
简梨娜
ZHU Xiaoting;XU Jian;GUO Jiangtao;ZHANG Yongping;LIU Jie;JIAN Lina(College of Pharmaceutical Sciences,Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China;National Engineering Technology Research Center for Miao Medicine,Guiyang 550025,China;Guizhou Engineering Technology Research Center for Processing and Preparation of Traditional Chinese Medicine and Ethnic Medicine,Guiyang 550025,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2024年第17期2318-2327,共10页
Chinese Journal of Modern Applied Pharmacy
基金
国家自然科学基金委员会-贵州省人民政府联合基金(U1812403-2)
贵州省科技计划项目(黔科合基础-ZK[2022]一般463)
贵州省高层次创新型人才(黔科合平台人才-GCC[2023]037)
贵州中医药大学学术新苗项目(贵科合学术新苗[2023]-12号)。